These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19926048)

  • 1. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter?
    Brener SJ
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1092-4. PubMed ID: 19926049
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Aylward PE; Gallo R; Bode C; Steg G; Steinhubl SR; Montalescot G;
    Am Heart J; 2010 Jan; 159(1):110-6. PubMed ID: 20102875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
    Díez JG; Medina HM; Cheong BY; O'Meallie L; Ferguson JJ
    Tex Heart Inst J; 2009; 36(2):98-103. PubMed ID: 19436801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
    Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
    Collet JP; Huber K; Cohen M; Zeymer U; Goldstein P; Pollack C; Silvain J; Henry P; Varenne O; Carrié D; Coste P; Angioi M; Le Breton H; Cayla G; Elhadad S; Teiger E; Filippi E; Aout M; Vicaut E; Montalescot G;
    Am J Cardiol; 2013 Nov; 112(9):1367-72. PubMed ID: 24012033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.
    Lindsey JB; Marso SP; Pencina M; Stolker JM; Kennedy KF; Rihal C; Barsness G; Piana RN; Goldberg SL; Cutlip DE; Kleiman NS; Cohen DJ;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1074-82. PubMed ID: 19926047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial.
    Pellaton C; Cayla G; Silvain J; Zeymer U; Cohen M; Goldstein P; Huber K; Pollack C; Kerneis M; Collet JP; Vicaut E; Montalescot G;
    Am Heart J; 2015 Oct; 170(4):778-86. PubMed ID: 26386802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
    Montalescot G; Zeymer U; Silvain J; Boulanger B; Cohen M; Goldstein P; Ecollan P; Combes X; Huber K; Pollack C; Bénezet JF; Stibbe O; Filippi E; Teiger E; Cayla G; Elhadad S; Adnet F; Chouihed T; Gallula S; Greffet A; Aout M; Collet JP; Vicaut E;
    Lancet; 2011 Aug; 378(9792):693-703. PubMed ID: 21856483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).
    Bertel O; Ramsay D; Wettstein T; Kurz DJ; Stettler I; Straumann E; Frielingsdorf J; Maurer D; Naegeli B
    EuroIntervention; 2010 Aug; 6(3):407-12. PubMed ID: 20884422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
    Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
    J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.